#SGOmtg Twitter Highlights - Research Highlights Monday, March 26, 2018

Monday March 26th was another day of important presentations at the SGO Annual meeting. Some results may change treatment protocols going forward.

Here are the tweets I found of most importance.

Cervical Cancer - Minimally invasive surgery *this one may change how early cervical cancer is treated

Do we need to rethink minimally invasive surgery for cervix? #SGOMtg pic.twitter.com/XTLgg5IO0t

— Erin Stevens (@erinstevensmd) March 26, 2018

Dr Raih Hain of @MDAndersonNews presenting surprising results- our patients with early #cervicalcancer have been doing worse since the adoption of min invasive surgery. Time to rethink practice at the #SGOMtg pic.twitter.com/K3afaUynxe

— Dr. Robert Dood (@DrRobDood) March 26, 2018

Ovarian Cancer Debulking Surgery

No residual disease remains a goal of OvCa debulking surgery. Single site optimal improves PFD and OS as compared to multisite optimal or suboptimally debulked OVCA. Manning-Geist et al #SGOMtg pic.twitter.com/KP0P9SeEAK

— Rick Boulay,MD (@journeycancer) March 26, 2018

Excellent talk on #ovariancancer surgery by @AnilSoodMD at the #SGOMtg @SGO_org @MDAndersonNews pic.twitter.com/IiXT5YbBG2

— Kathleen Schmeler MD (@kmschmeler) March 26, 2018

Ovarian Cancer - Niraparib and Pembrolizumab

Late Breaking Abstract: Dr. Konstatinopoulos presents results of niraparib and pemrolizumab combo in heavily pretreated platinum resistant ovarian cancer #SGOmtg #gyncsm pic.twitter.com/zWhSRVAhx4

— Annie Ellis (@Stigetta) March 26, 2018

Ovarian Cancer - Olaparib and Durvalumab

Olaparib + durvalumab ORR of 72% in plt sens recurrent #ovariancancer gBRCA pos patients #SGOMtg pic.twitter.com/hio2vSVxmM

— Alpa Nick (@AlpaNick) March 26, 2018

Late Breaking Abstract session: Dr. Drew presents results of MEDIOLA basket trial of olaparib and durvalumab combo in relapsed BRCA+ platinum sensitive ovarian cancer #SGOmtg #gyncsm pic.twitter.com/lycZZlxYYR

— Annie Ellis (@Stigetta) March 26, 2018

 Ovarian Cancer- Metastasis and DDR2 experssion

M Greenwade presents work to understand stromal expression of DDR2 and control ovarian cancer metastasis #SGOmtg #gyncsm pic.twitter.com/wGE4w44Qaf

— Annie Ellis (@Stigetta) March 26, 2018

Palliative care

Palliative care: not just for end of life. New model includes life prolonging care from diagnosis. Very important for QoL throughout treatment and beyond! #SGOMtg #gyncsm pic.twitter.com/tyGDFxkACz

— Annie Ellis (@Stigetta) March 25, 2018

Survivorship / BMI and Risk

Endometrial cancer is one of the 3 obesity-driven cancers in women. Only 1% of #endometrial and #ovarian cancer patients are meeting the 2006 ACS guidelines for #cancersurvivors - Dr. Von Gruenigen #SGOMtg pic.twitter.com/EAX08fQOqN

— Ali Saiz (@aulyouneedisluv) March 26, 2018

Fantastic sunrise seminar on survivorship! Survivors need to be empowered with information after front line treatment. Reduce risk and screen for secondary cancers. #sgomtg #gyncsm pic.twitter.com/OLyOW0E4lL

— Annie Ellis (@Stigetta) March 26, 2018

Lay navigation

Lay navigation (non clinical) for pts w/ gyn cancers. Navigation triggered via distress scores/risk factors, then triage pt to resources. Study: how did this service impact cost? 1052 patients; 37% navigated. Navigated pts=57% ⬇ in total costs & ⬇ in hospitalization#SGOmtg

— Erica Bednar (@EMBOSU) March 26, 2018

Granulosa Cell tumors

Excellent presentation by @RTylerHillmanMD identifying KMT2D mutations in granulosa cell tumors #SGOMtg pic.twitter.com/EhcSeeq3ci

— Aaron Shafer (@aaronshafer99) March 26, 2018

@RTylerHillmanMD presents high quality sequencing used to identify KMT2D predicting recurrence in granulosa cell #ovariancancer @MDAndersonNews #SGOMtg pic.twitter.com/imZZcpSYuz

— Dr. Robert Dood (@DrRobDood) March 26, 2018

Thanks Dr Dood, Erica Bednar, Annie Ellis, Ali Saiz, Alpa Nick, Rick Boulay, Erin Stevens and Kathleen Schmeler for sharing on Twitter during the meeting.

Dee
Every Day is a Blessing!